More answers like this
GPT-5Sep 28, 2026openai/gpt-5-2025-08-07
Should AI development be paused or restricted?
Short answer: Not a blanket pause, but targeted restrictions and, in some areas, temporary pauses make sense.
Why not pause everything
•A broad moratorium would slow medical, climate, accessibility, and safety research, push work to less transparent actors, and entrench incumbents—without reliably reducing risk.
Where pauses or hard restrictions are justified
•Capability-specific moratoria until safeguards exist: models or toolchains that materially lower barriers to biological misuse, large-scale cyber‑exploitation, autonomous replication/persistence, or weapon targeting.
•Weight releases above a danger threshold: don’t open‑release models that demonstrate high-risk capabilities until robust mitigations and monitoring are in place.
How to restrict smartly (risk-proportionate)
•Separate stages: allow research; gate training at frontier scales; require evidence and controls for deployment; regulate certain end-uses.
•Pre‑deployment evaluations: standardized red‑teaming and domain‑expert testing for bio/cyber/critical‑infrastructure risks; publish safety cases.
•Compute governance: reporting for large training runs, audits of safety practices beyond defined FLOP thresholds, and licensing for the very largest systems.
•Independent oversight: third‑party audits, incident reporting, and post‑deployment monitoring for model upgrades and fine‑tunes.
•Guardrails in deployment: tool-use sandboxing, rate limits, provenance/watermarking, authenticated access for high‑risk features, and “safety brakes” for critical domains.
•Transparency with accountability: model/system cards, eval results, documented mitigations, and liability standards for foreseeable harms.
•Focus on bad uses, not broad capability: ban clearly harmful applications (e.g., nonconsensual deepfakes, voter suppression bots) while allowing low‑risk, beneficial uses.
A practical policy summary
•Restrict and sometimes pause specific dangerous capabilities and releases.
•License and audit only at the frontier; keep most development open but responsible.
•Tie obligations to demonstrated risk, not just model size.
If you’re asking from a policy, company, or researcher perspective, I can tailor this into a concrete checklist.